AR083565A1 - Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen - Google Patents

Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen

Info

Publication number
AR083565A1
AR083565A1 ARP110103963A ARP110103963A AR083565A1 AR 083565 A1 AR083565 A1 AR 083565A1 AR P110103963 A ARP110103963 A AR P110103963A AR P110103963 A ARP110103963 A AR P110103963A AR 083565 A1 AR083565 A1 AR 083565A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
independently
cyclopropyl
alkoxy
Prior art date
Application number
ARP110103963A
Other languages
English (en)
Inventor
Min Zhong
Leping Li
Original Assignee
Presidio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083565(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Presidio Pharmaceuticals Inc filed Critical Presidio Pharmaceuticals Inc
Publication of AR083565A1 publication Critical patent/AR083565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula estructural (1), donde: L1, L2 y L3 junto con los carbonos ligados al anillo aromático forman un anillo de 5 - 12 miembros que contiene 0 - 4 heteroátomos de N, O, S, P y/o Si; L1, L2, o L3 se selecciona independientemente de un grupo de sustituyentes divalentes que consiste en un enlace, -O-, -C(R15R16)-, -NR3-, -S(O)n-, -P(O)-, -Si(R4R5)-, -C(O)-, -C(O)O-, y alquilo, alquenilo, alcoxilo, cicloalquilo, cicloalcoxilo, heterociclo, arilo, heteroarilo, amida, carbamato, urea y sulfonamida sustituidos; n es 0, 1 ó 2; U o V es, independientemente, CH, N, CF, CCI, o CCN; W, X, o Z es, independientemente, C o N; Y es NRN, N, O, S, Se, o -CRaRb; RN es hidrógeno, alquilo C1-4, cicloalquilo C3-6, heterociclo C4-5, arilo, heteroarilo, amida, sulfonamida o carbamato; Ra, Rb es, independientemente, hidrógeno, metilo o juntos forman un cicloalquilo C3-6 que porta 0 - 1 heteroátomo de O ó NR3; R1 se selecciona entre hidrógeno, haluro, -CF3, -CN, -C(O)H, -C(O)OR6-, -C(O)NHR7, -C(O)N(OH)R7, -C(=NR7)OMe, -C(=NOMe)NHR7, C(=NOH)NHR7, -CH(CF3)NHR8, CH(CN)NHR9, -S(O)2NHR10, -C(=NCN)NHR11, y o un resto del grupo de formulas (2); R2 es un arilo o heteroarilo sustituido o no sustituido; R3 se selecciona del grupo formado por hidrógeno, alquilcarbonilo, cicloalquilcarbonilo, alcoxilcarbonilo, cicloalcoxicarbonilo, alquilsulfonilo y cicloalquilsulfonilo; R4 y R5 son, independientemente, metilo, etilo o ciclopropilo; R6 es hidrógeno, alilo, alquilo C1-4, ciclopropilo o bencilo; R7 es hidrógeno, alquilo  C1-4, ciclopropilo, alcoxilo C1-4, ciclopropoxi, alquilsulfonilo o cicloalquilsulfonilo; R8, R9, R10, o R11 es, independientemente, hidrógeno, alquilo C1-4, ciclopropilo, alcoxilo C1-4, o ciclopropoxi; y R15, R16 es, independientemente, hidrógeno, hidroxilo, azida, alquenilo C2-4, alquinilo C2-4, alquilo C1-4, ciclopropilo, alcoxilo C1-4, o ciclopropoxi o R15 y R16 juntos son un carbonilo o alquenilideno C1-4 o R15 y R16 unidos con el carbono al que están ligados, forman un anillo de 3 - 6 miembros que opcionalmente contiene 0 - 3 heteroátomos de O, NRN y/o S.
ARP110103963A 2010-10-26 2011-10-26 Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen AR083565A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40697210P 2010-10-26 2010-10-26
US201161438429P 2011-02-01 2011-02-01
US201161524220P 2011-08-16 2011-08-16

Publications (1)

Publication Number Publication Date
AR083565A1 true AR083565A1 (es) 2013-03-06

Family

ID=45994336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103963A AR083565A1 (es) 2010-10-26 2011-10-26 Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen

Country Status (21)

Country Link
US (4) US20130302282A1 (es)
EP (1) EP2632261B1 (es)
JP (1) JP5731004B2 (es)
KR (1) KR101594166B1 (es)
CN (1) CN103269586B (es)
AR (1) AR083565A1 (es)
AU (1) AU2011320696B2 (es)
BR (1) BR112013009789A2 (es)
CA (1) CA2815537A1 (es)
CL (1) CL2013001141A1 (es)
CO (1) CO6700883A2 (es)
EA (1) EA025151B1 (es)
HK (1) HK1185763A1 (es)
IL (1) IL225853A0 (es)
MX (1) MX2013004655A (es)
NZ (1) NZ609564A (es)
PE (1) PE20140109A1 (es)
SG (1) SG189985A1 (es)
TW (1) TWI486348B (es)
WO (1) WO2012058125A1 (es)
ZA (1) ZA201303752B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767887A1 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
ES2644804T3 (es) * 2010-01-27 2017-11-30 Ab Pharma Ltd Compuestos poliheterocíclicos como inhibidores de HCV
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
KR101594166B1 (ko) * 2010-10-26 2016-02-15 프레시디오 파마슈티칼스, 인코포레이티드 C형 간염 바이러스의 억제제
SE1450131A1 (sv) * 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
WO2014110066A1 (en) 2013-01-10 2014-07-17 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
EA201691777A1 (ru) 2014-03-21 2016-12-30 Бристол-Маерс Сквибб Компани Содержащие цианогруппу соединения азабензофурана для лечения гепатита с
US9920036B2 (en) * 2014-03-21 2018-03-20 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C
US9914739B2 (en) 2014-03-21 2018-03-13 Bristol-Myers Squibb Company 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C
WO2015179392A1 (en) 2014-05-21 2015-11-26 Bristol-Myers Squibb Company 2-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c
EP3154963A1 (en) 2014-06-11 2017-04-19 Bristol-Myers Squibb Company Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c
WO2016022513A1 (en) 2014-08-05 2016-02-11 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
US10202403B2 (en) 2014-10-02 2019-02-12 Bristol-Myers Squibb Company Macrocyclic benzofuran compounds for the treatment of hepatitis C
WO2016133972A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis c
WO2016133961A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors
US10087167B2 (en) 2015-02-19 2018-10-02 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as HCV inhibitors
US10131645B2 (en) 2015-02-19 2018-11-20 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as HCV inhibitors
WO2016133948A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
US11831699B2 (en) * 2016-09-08 2023-11-28 Harmonic, Inc. Using web-based protocols to assist graphic presentations when providing digital video

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741A (en) 1850-10-29 Cak-cottpling
US347A (en) 1837-08-08 dixon
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
DE69736984T2 (de) 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
CN100509797C (zh) 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
DE60221875T2 (de) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren
HN2003000348A (es) 2002-11-01 2008-10-14 Viropharma Inc Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
ES2456702T3 (es) * 2003-05-09 2014-04-23 Boehringer Ingelheim International Gmbh Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
EP1746888A2 (en) 2004-05-13 2007-01-31 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2618682C (en) * 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007059421A2 (en) 2005-11-10 2007-05-24 Wyeth Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
EP2038253A1 (en) 2006-05-30 2009-03-25 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
GB0614940D0 (en) 2006-07-27 2006-09-06 Arternis Intelligent Power Ltd Vehicle traction and stability control system employing control of fluid quanta
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008082725A1 (en) 2006-12-29 2008-07-10 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
CN101687789A (zh) 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
GB0707000D0 (en) * 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
CA2685069C (en) 2007-05-23 2019-01-15 Vgx Pharmaceuticals, Inc. Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
EP2408761B1 (en) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
KR100903410B1 (ko) 2007-10-16 2009-06-18 (주)다산알앤디 자동속도조절 러닝머신 및 그 제어모듈
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0907885A2 (pt) * 2008-02-14 2015-07-21 Hoffmann La Roche Compostos antiviras hetrocíclicos
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
CN101635673B (zh) 2008-07-25 2012-01-25 华为技术有限公司 预订路径的方法、***及路径计算客户、路径计算单元
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2010092550A (ja) 2008-10-09 2010-04-22 Hitachi Global Storage Technologies Netherlands Bv 磁気記録ヘッド、その製造方法及び磁気記録再生装置
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
NZ593806A (en) 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
BRPI1005828A2 (pt) * 2009-02-27 2017-07-18 Siga Tech Inc composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida
CA2761279A1 (en) 2009-05-20 2010-11-25 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2516430B1 (en) * 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AU2011224698A1 (en) * 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
WO2011112186A1 (en) 2010-03-10 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
JP2013522192A (ja) 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物
US8324239B2 (en) * 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
KR101594166B1 (ko) * 2010-10-26 2016-02-15 프레시디오 파마슈티칼스, 인코포레이티드 C형 간염 바이러스의 억제제
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
NZ609564A (en) 2015-06-26
ZA201303752B (en) 2014-04-30
PE20140109A1 (es) 2014-02-23
WO2012058125A1 (en) 2012-05-03
EA025151B1 (ru) 2016-11-30
US20120251497A1 (en) 2012-10-04
SG189985A1 (en) 2013-06-28
JP2014500861A (ja) 2014-01-16
EA201390433A1 (ru) 2013-10-30
US20140286899A1 (en) 2014-09-25
US9085587B2 (en) 2015-07-21
MX2013004655A (es) 2013-08-27
BR112013009789A2 (pt) 2016-07-19
US9309260B2 (en) 2016-04-12
AU2011320696B2 (en) 2016-07-21
EP2632261B1 (en) 2016-07-13
AU2011320696A1 (en) 2013-05-23
CL2013001141A1 (es) 2013-10-04
CN103269586B (zh) 2015-07-15
CA2815537A1 (en) 2012-05-03
KR20130121111A (ko) 2013-11-05
TWI486348B (zh) 2015-06-01
US20120276051A1 (en) 2012-11-01
JP5731004B2 (ja) 2015-06-10
TW201245195A (en) 2012-11-16
EP2632261A1 (en) 2013-09-04
US20130302282A1 (en) 2013-11-14
EP2632261A4 (en) 2013-11-27
HK1185763A1 (zh) 2014-02-28
US8614207B2 (en) 2013-12-24
CO6700883A2 (es) 2013-06-28
IL225853A0 (en) 2013-06-27
CN103269586A (zh) 2013-08-28
KR101594166B1 (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
AR083565A1 (es) Compuestos heterociclicos utiles para tratar infecciones por vhc en humanos y composiciones farmaceuticas que los contienen
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
RU2012124056A (ru) Спирооксиндольные антагонисты mdm2
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CR11682A (es) Compuestos y composiciones como moduladores de la actividad de tlr
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
TW200640885A (en) Novel haoalkanesulfonylaniline derivatives, weed killer and the use methods thereof
AR093403A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
AR081653A1 (es) Inhibidores del virus de la hepatitis c
AR059512A1 (es) Derivados de piridina -2- carboxamida
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR057033A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
AR100312A1 (es) Compuestos de diaminotriazina
RU2502730C2 (ru) Сульфонамидные соединения и их применение
NZ601967A (en) Pde10 inhibitors and related compositions and methods
RU2016135922A (ru) Терапевтические соединения и композиции

Legal Events

Date Code Title Description
FB Suspension of granting procedure